The new line, which has automated visual inspection and container closure integrity testing features, will have a >5 fold increased filling speed allowing temperature sensitive biologics to be filled. Recipharm will also provide secondary packaging and labelling from the facility.
The new line will be fully commissioned in Q2 2022 and is expected to be operational for commercial production in Q3 2022. Recipharm is also in the process of implementing new cleanroom facilities and labs for microbiology and in-process controls.
The site in Monts is one of Recipharm’s principal sterile manufacturing facilities and has seen significant growth in recent years in the fill & finish of an mRNA vaccine. It will continue to deliver batches of COVID-19 vaccines to support vaccination programmes around the world.
The investment is part of a wider growth plan which also sees the CDMO investing in new fill and finish facilities in India (1 and 2) and Morocco. The additional sites will complement Recipharm’s existing sites in France, Germany and Italy and will be focused on securing approvals from regulators in Europe and the U.S.
